Stocksigma LogoStocksigma Logo

Sudarshan Pharma Industries Investor Presentation Highlights Expansion and Strong Financial Growth

Sudarshan Pharma Industries reported consolidated FY'26 revenue of Rs 703.06 Cr, up 39.2% YoY, with EBITDA rising 25.4% YoY to Rs 49.3 Cr and PAT

Sudarshan Pharma Industries Investor Presentation Highlights Expansion and Strong Financial Growth

Sudarshan Pharma Industries Ltd 路 Investor Presentation 路 07 Nov 2026, 9:54 pm

Sudarshan Pharma Industries Investor Presentation Highlights Expansion and Strong Financial Growth Sudarshan Pharma Industries reported consolidated FY'26 revenue of Rs 703.06 Cr, up 39.2% YoY, with EBITDA rising 25.4% YoY to Rs 49.3 Cr and PAT increasing 102% YoY to Rs 23.3 Cr. For Sep'26, half-year revenue stood at Rs 391.39 Cr with PAT of Rs 13.39 Cr. Strategic milestones include acquiring Rs 25.50 Cr capex from Srigen Lifesciences, securing GMP and ISO certifications for its Hyderabad API unit, proposing a $20 Mn FCCB allotment, and targeting over Rs 100 Cr in exports for FY'27.

Original exchange filing (PDF)

More announcements from Sudarshan Pharma Industries Ltd

All Sudarshan Pharma Industries Ltd announcements